ID: ALA189421

Max Phase: Preclinical

Molecular Formula: C21H16FN5S

Molecular Weight: 389.46

Molecule Type: Small molecule

Representations

Canonical SMILES:  N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccc(F)c2)n1

Standard InChI:  InChI=1S/C21H16FN5S/c22-15-5-3-4-14(12-15)8-10-24-21-25-11-9-17(27-21)16(13-23)20-26-18-6-1-2-7-19(18)28-20/h1-7,9,11-12,26H,8,10H2,(H,24,25,27)/b20-16+

Standard InChI Key:  VVGCDPREGFDTDN-CAPFRKAQSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 389.46

Molecular Weight (Monoisotopic): 389.1110

AlogP: 4.68

#Rotatable Bonds: 5

Polar Surface Area: 73.63

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.25

CX Basic pKa: 2.59

CX LogP: 4.62

CX LogD: 4.62

Aromatic Rings: 3

Heavy Atoms: 28

QED Weighted: 0.62

Np Likeness Score: -1.53

References

1. Gaillard P, Jeanclaude-Etter I, Ardissone V, Arkinstall S, Cambet Y, Camps M, Chabert C, Church D, Cirillo R, Gretener D, Halazy S, Nichols A, Szyndralewiez C, Vitte PA, Gotteland JP..  (2005)  Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase.,  48  (14): [PMID:15999997] [10.1021/jm0310986]

Source

Source(1):

• Scientific Literature